

# **Imaging Overview for Vulnerable Plaque: Data from IVUS Trial and An Introduction to VH-IVUS Imaging**

***Gary S. Mintz, MD***

**Cardiovascular Research Foundation  
New York, NY**



CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER


- Today, in reality, almost everything that we currently know about vulnerable plaque has come either from histopathology or from in vivo detection of plaque rupture or study of patients who present with acute coronary syndromes - NOT from prospective correlative studies or prospective identification of vulnerable plaques before they rupture, rapidly progress, or thrombose.
- To my knowledge, there are only three, retrospective IVUS studies relating lesion findings to late events – and no trial data




# Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by IVUS before an acute coronary syndrome

- 114 coronary sites from 106 patients
- 16 pts had an acute event 1-24 months ( $21.8 \pm 6.4$  months) post index IVUS
- 12 pts had the event  $4.0 \pm 3.4$  months (range 1 to 8 months) at the same sites where preexisting atherosclerotic disease had been demonstrated by IVUS

	Sites related to acute events	Sites not related to acute events	p
Plaque burden	$67 \pm 9\%$	$57 \pm 12\%$	$<0.05$
Shallow echolucent zones	8/12	4/90	$<0.05$



Proximal 0 —————> 3mm —————> 12mm




EEM CSA = 21.0mm<sup>2</sup>  
Lumen CSA = 9.5mm<sup>2</sup>  
P+M CSA = 11.5mm<sup>2</sup>

EEM CSA = 23.5mm<sup>2</sup>  
Lumen CSA = 5.5mm<sup>2</sup>  
P+M CSA = 18.0mm<sup>2</sup>

EEM CSA = 13.7mm<sup>2</sup>  
Lumen CSA = 9.3mm<sup>2</sup>  
P+M CSA = 4.4mm<sup>2</sup>


# Clinical Follow up in 357 Intermediate Lesions in 300 Pts Deferred Intervention After IVUS Imaging

**IVUS MLD (mm)**




**QCA MLD (mm)**

**Death/MI/TLR**



**IVUS MLA (mm<sup>2</sup>)**

**TLR**




**IVUS MLA (mm<sup>2</sup>)**

- Death/MI/TLR @ (mean) 13 mos = 8% overall (2% death/MI and 6% TLR)
- Death/MI/TLR @ (mean) 13 mos = 4.4% in lesions with MLA >4.0mm<sup>2</sup>
- Only independent predictor of death/MI/TLR was IVUS MLA (p=0.0041)
- Independent predictors of TLR were DM (p=0.0493) and IVUS MLA (p=0.0042)
- Although the number of patients with death/MI was small (n=6), the only independent predictor was IVUS MLD (p=0.0498)


# Relationship Between LM Plaque Progression and Non-LM Events

% $\Delta$ P&M/yr




\*Death, MI, USA, or PCI or another lesion

# LM Plaque Progression As a Predictor of Non-LM Cardiovascular Events



$p < 0.001$  (vs. no events)




Myocardial infarction (n=5)


Unstable angina (n=7)

PCI of new de-novo lesion (n=6)

No events (n=38)




0 —————> 1mm —————> 4mm






# Three Vessel IVUS Imaging in 24 Pts with ACS and Positive Tn


- 50 ruptured plaques
  - 9 culprit lesion
  - 41 nonculprit lesion
- 19 pts had at least 1 nonculprit plaque rupture (79%)
  - 17 pts had 1 plaque rupture in a second artery
  - 3 pts had plaque ruptures in all 3 arteries



# Location of 273 ruptured plaques in 158 patients with ACS and 48 patients with stable angina and three vessel IVUS



Length of artery imaged beginning at the coronary ostium (mm)



Distance from coronary ostium (mm)


# Symptoms in 254 patients with 300 plaque ruptures in 257 arteries

■ Asymptomatic

■ Stable angina


■ Peri MI

■ USA



(Maehara et al  
*J Am Coll Cardiol* 2002;40:904-10)

# # of ruptured plaques per patient with stable angina (n=113)




(Hong et al  
*Circulation* 2004;110:928-33)



# Comparison of Culprit & Non-Culprit Rupture Sites in ACS Patients and Rupture Sites in Non-ACS Patients

■ ACS Culprit Plaque Ruptures (N=35)    ■ ACS Non-Culprit Plaque Ruptures (N=20)    ■ Non-ACS Plaque Ruptures (N=27)




*Independent predictors of ACS were MLA and thrombus (both p=0.01)*



0

2mm

6mm




CARDIOVASCULAR RESEARCH  
FOUNDATION



COLUMBIA UNIVERSITY  
MEDICAL CENTER

# Association of positive remodeling and ACS




(Schoenhagen et al. *Circulation* 2000;101:598-603) (Prati et al. *Circulation* 2003;107:2320-5)

# Calcium is less severe and more “spotty” in unstable lesions

	MI (n=61)	Unstable angina (n=70)	Stable angina (n=47)
<b>No calcification</b>	26%	41%	21%
<b>Spotty calcification</b>	51%	40%	30%
<b>Intermediate calcification</b>	15%	16%	11%
<b>Extensive calcification</b>	8%	3%	38%

*p*<0.0001

# IVUS profile of ruptured plaques: Insights into pre-rupture morphology (n=112 culprit ruptured plaques)






	Mean $\pm$ 1SD	CoV	10 <sup>th</sup> Percentile	90 <sup>th</sup> Percentile
<b>Reference</b>				
<b>Lumen CSA</b>	<b>11.7 <math>\pm</math> 3.5</b>	<b>0.29</b>	<b>8.1</b>	<b>15.3</b>
EEM CSA	20.2 $\pm$ 5.6	0.27	14.2	26.7
P&M CSA	8.5 $\pm$ 3.0	0.35	4.9	12.4
Plaque Burden	0.42 $\pm$ 0.75	0.18	0.31	0.49
<b>Lesion</b>				
<b>Lumen CSA</b>	<b>4.9 <math>\pm</math> 2.7</b>	<b>0.55</b>	<b>2.1</b>	<b>8.6</b>
<b>EEM CSA</b>	<b>20.8 <math>\pm</math> 6.0</b>	<b>0.29</b>	<b>14.3</b>	<b>28.5</b>
P&M CSA	15.9 $\pm$ 4.9	0.31	9.8	22.4
Min P&M Th	0.5 $\pm$ 0.3	0.58	0.2	1.0
<b>Max P&amp;M Th</b>	<b>2.3 <math>\pm</math> 0.6</b>	<b>0.25</b>	<b>1.6</b>	<b>3.0</b>
Eccentricity	0.32 $\pm$ 0.23	0.71	0.09	0.66
<b>Plaque Burden</b>	<b>0.76 <math>\pm</math> 0.10</b>	<b>0.12</b>	<b>0.63</b>	<b>0.88</b>
AS	0.57 $\pm$ 0.19	0.34	0.28	0.80
<b>RI</b>	<b>1.10 <math>\pm</math> 0.20</b>	<b>0.18</b>	<b>0.87</b>	<b>1.38</b>
Arc of Ca <sup>++</sup>	46.9 $\pm$ 51.2	1.09	0	106.7

While the sensitivity of these findings is high, the specificity is low.

# Are all vulnerable plaques thin-cap fibroatheromas?



## Different Types of Vulnerable Plaque





←→  
70% of ACS  
culprit lesions



# In vivo comparison of OCT and angioscopy in assessing culprit lesions in 30 AMI patients

## Plaque rupture



## Plaque erosion






# Virtual Histology™ IVUS

Only the envelope amplitude (echo intensity) is used in formation of the gray-scale IVUS image


Eight amplitude and frequency parameters are used in Virtual Histology



Frequency of echo signal can also vary, depending on the tissue




IVUS B scan



Movat pentachrome stain



Thin plate spline morphing  
after which the computer  
was taught to recognize four  
basic tissue types



# In vitro Validation of VH Tissue Characterization

Eagle Eye VH Accuracy  
VH IVUS vs histopathology from fresh post-mortem coronary arteries

	Sensitivity	Specificity	Predictive Accuracy
<b>Fibrous tissue (n=162)</b>	84.0%	98.8%	92.8%
<b>Fibrofatty (n=84)</b>	86.9%	95.1%	93.4%
<b>Necrotic core (n=69)</b>	97.1%	93.8%	94.4%
<b>Dense calcium (n=92)</b>	97.8%	99.7%	99.3%

## EuroIntervention

### **Tissue characterisation using intravascular radiofrequency data analysis: recommendations for acquisition, analysis, interpretation and reporting**


Héctor M. García-García<sup>1</sup>, MD, MSc; Gary S. Mintz<sup>2</sup>, MD, FACC; Amir Lerman<sup>3</sup>, MD, FACC; D. Geoffrey Vince<sup>4</sup>, PhD; M. Pauliina Margolis<sup>4</sup>, MD, PhD; Gerrit-Anne van ES<sup>5</sup>, PhD; Marie-Angèle M. Morel<sup>5</sup>, BSc; Anuja Nair<sup>4</sup>, PhD; Renu Virmani<sup>6</sup>, MD, FACC; Allen P. Burke<sup>6</sup>, MD, FACC; Gregg W. Stone<sup>2</sup>, MD, FACC; Patrick W. Serruys<sup>1\*</sup>, MD, PhD, FACC, FESC

*1. Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands; 2. Cardiovascular Research Foundation, New York, USA; 3. Mayo Clinic, Rochester, Minnesota, USA; 4. Volcano Corporation, Rancho Cordova, California, USA; 5. Cardialysis, BV, Rotterdam, The Netherlands; 6. CVPPath Institute, Inc., Gaithersburg, Maryland, USA*




# Development of Human Coronary Atherosclerosis

Adaptive  
Intimal  
thickening




Intimal  
xanthoma








Pathologic  
intimal  
thickening



Fibrous  
cap atheroma




Thin-cap  
Fibroatheroma



- Smooth muscle cells
- Macrophage foam cells
- Extracellular lipid
- Cholesterol clefts
- Necrotic core

- Calcified plaque
- Hemorrhage
- Thrombus
- Healed thrombus
- Collagen

FC = fibrous cap  
LP = lipid pool  
NC = necrotic core



Pathological  
intimal  
thickening (PIT)

Thin-cap  
fibroatheroma  
(TCFA)

Thick-cap  
fibroatheroma  
(ThFA)

Fibrotic

Fibrocalcific



# Morphometry of different plaque types



	IEL mm <sup>2</sup>	Plaque burden %	Necrotic core %
Pathologic intimal thickening (PIT) (n=125)	6.5	43.0	0.1
Fibroatheroma (n=262)	9.2	64.5	11.2
TCFA (n=46)	12.8	67.0	21.6
Plaque rupture (n=55)	13.2	79.8	29.0

	TCFA (n=64)	Plaque Rupture (n=69)
IEL Area mm <sup>2</sup>	11.99	12.63
Plaque Area	8.74	10.35
Plaque burden %	69.2	75.1
% Necrotic core	24.3	32.2
% Calcification	8.95	5.77
% Macrophage	4.56	3.78
Mean cap thickness (μ m)	39	35


PIT is the likely precursor lesion of fibroatheroma, but the mechanisms responsible for this conversion are poorly understood. . .

# Thin Cap Fibroatheroma (TCFA)


“Thin Cap Fibro-Atheroma (TCFA)” or “Vulnerable Plaque” – Confluent necrotic core >10% of total plaque and located at the lumen in 3 consecutive frames. Based on the presence or absence of Ca, the length of the NC, or signs of previous ruptures, TCFA can be further sub-classified for the purpose of risk assessment



<5% calcium





>5% calcium



multiple layers

*Still further sub-classification can be based on presence of luminal narrowing.*

“TCFA without significant narrowing” - plaque burden <50% on IVUS and/or less than 25% narrowing on angiogram. (Pathologic data suggests that TCFA without significant plaque burden are less “vulnerable”)



“Highest Risk TCFA”

- Confluent NC>20%
- No evidence of fibrotic cap
- Calcium >5%
- Remodeling index >1.05
- >50% plaque burden by IVUS

(Pathologic data suggests that TCFA with significant plaque burden are the most vulnerable)




# Healed ruptures are common in patients with acute events


- In 142 men with sudden cardiac death, the mechanism of death was presumed to be acute plaque rupture with acute thrombus in 44, acute plaque erosion with acute thrombus in 23, stable plaque with healed MI in 41, and stable plaque without MI in 34
- There were 189 healed rupture sites. Healed ruptures were present in 75% of hearts with acute plaque rupture and 80% of hearts with stable plaque and healed MI
- Of the 44 acute rupture sites, 9 showed 1 healed previous rupture site, 9 showed 2 healed previous rupture sites, 9 showed 3 healed previous rupture sites, and 6 showed 4 healed previous rupture sites.
- Acute ruptures at sites of  $\geq 3$  healed previous ruptures demonstrated greater underlying plaque burden ( $94 \pm 4\%$ ) than those without healed previous rupture ( $74 \pm 12\%$ ).



# Mean plaque burden increases with number of prior rupture sites










Number of prior ruptures, healed rupture sites



Number of prior ruptures, acute rupture sites

11% of plaque ruptures are virgin

Multiple small calcific deposits by greyscale IVUS, multiple necrotic cores by VH-IVUS



- **Greyscale IVUS findings are ubiquitous in diffuse/advanced coronary atherosclerosis and, therefore, of limited ability to predict events.**
- **VH-IVUS criteria were based on presumptive histologic evidence. But its ability to detect and assess the risk of a specific lesion will depend NOT on correlation with histopathology, but on the ability to predict future events.**
- **Perhaps PROSPECT will validate these assumptions. Perhaps not.**







TCT2009

TRANSCATHETER CARDIOVASCULAR THERAPEUTICS

# San Francisco

September 21-26, 2009

The Moscone Center  
San Francisco, CA



CARDIOVASCULAR RESEARCH  
FOUNDATION

*A Passion for Innovation*

[www.crf.org](http://www.crf.org)



TCT2009

TRANSCATHETER CARDIOVASCULAR THERAPEUTICS

[www.tctconference.com](http://www.tctconference.com)